Moreover the anti-tumor effects obtained here by NCL-recognizing nanoparticles in vitro and in pre-clinical models of human NB represent the proof-of-concept supporting cell surface NCL as a potentially druggable cellular marker for NB patients. Here, NUCLEOLIN is linked to neoplasm.